Galectin Therapeutics (GALT)

• Market cap: $86.6M
• 1 day: 0.73%
• 5 days: 9.52%
• 1 month: -14.29%
• 3 months: 11.29%
• 6 months: -48.12%
• Year to date: 17.95%
• 1 year: -59.17%
• 5 years: -23.33%
• 10 years: -58.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 14

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

233% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 6

218% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 11

18% more funds holding

Funds holding: 79 [Q3] → 93 (+14) [Q4]

0.53% more ownership

Funds ownership: 15.68% [Q3] → 16.22% (+0.53%) [Q4]

23% less call options, than puts

Call options by funds: $5.86M | Put options by funds: $7.59M

45% less capital invested

Capital invested by funds: $26.8M [Q3] → $14.7M (-$12.1M) [Q4]